TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24212227

Group type: EXPERIMENTAL
Intervention: Recanalization (RC) with 20 G endodiathermy bipolar probe connected to a 7 W diathermy followed by bicanalicular intubation
Number of subjects: 209

Group type: COMPARATOR
Intervention: Standard external dacryocystorhinostomy (DCR)
Number of subjects: 209
Study: 21515812

Group type: EXPERIMENTAL
Intervention: Oral dosing of [D(10)]phenanthrene (10 μg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Inhalation of [D(10)]phenanthrene (10 μg)
Number of subjects: 16
Study: 18070096

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16854753

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 275

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 275
Study: 14691666

Group type: EXPERIMENTAL
Intervention: Closed circuit system
Number of subjects: 19

Group type: COMPARATOR
Intervention: Open circuit system
Number of subjects: 19
Study: 11066462

Group type: EXPERIMENTAL
Intervention: Tailored nutrition education letters
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standardized nutrition education letters
Number of subjects: 72
Study: 9062631

Group type: EXPERIMENTAL
Intervention: Alum-adsorbed Parietaria-pollen allergoid (Allergovit)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8383688

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Granisetron 160 micrograms/kg
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg (additional doses allowed)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Granisetron 160 micrograms/kg (additional doses allowed)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Granisetron (both doses)
Number of subjects: 504
Study: 6403935

Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Meptazinol (in preliminary study)
Number of subjects: 7
Study: 31957251

Group type: EXPERIMENTAL
Intervention: Icotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: WBI/WBI-chemotherapy
Number of subjects: 0
Study: 31184015

Group type: EXPERIMENTAL
Intervention: Intravesical sodium hyaluronate 50 ml 1 time per week for 12 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intravesical sodium hyaluronate combined with oral chondroitin sulfate 0.39 g (2 capsules 3 times a day) for 12 weeks
Number of subjects: 59
Study: 29729425

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Neighborhood stress
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Experiencing 3 to 4 hardships
Number of subjects: 412
Study: 27589414

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 100 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 200 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Number of subjects: 32
Study: 24576465

Group type: EXPERIMENTAL
Intervention: Television (TV) watching
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recreational computer use
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sedentary video game (VG) play
Number of subjects: 20
Study: 22207696

Group type: EXPERIMENTAL
Intervention: 16-channel multichannel compression (MCC)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (linear) condition
Number of subjects: 3
Study: 20530398

Group type: EXPERIMENTAL
Intervention: Facilitated implementation strategies for PCMH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-directed implementation strategies for PCMH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical record audits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient surveys
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinician and staff surveys
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethnographic observations
Number of subjects: 0
Study: 17572925

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 16618361

Group type: EXPERIMENTAL
Intervention: Total IgE measurement at 12 months of age
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Total IgE measurement at 18 months of age
Number of subjects: 715

Group type: COMPARATOR
Intervention: Skin prick test positivity to any allergen
Number of subjects: 715
Study: 15284972

Group type: EXPERIMENTAL
Intervention: Mini-incision (group 1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard incision (group 2)
Number of subjects: 42
Study: 11098350

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study: 8803359

Group type: EXPERIMENTAL
Intervention: Assessment + Book (30‐min telephone motivational interview plus book by mail)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Book by mail
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Assessment + Book
Number of subjects: 155
Study: 1814902

Group type: EXPERIMENTAL
Intervention: Azoran (1000 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Imuran (imported formulation)
Number of subjects: 14
Study: 6662172

Group type: EXPERIMENTAL
Intervention: terbutaline sulphate 31 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: terbutaline sulphate 63 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: terbutaline sulphate 125 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: terbutaline sulphate 250 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: terbutaline sulphate 2 X 250 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: terbutaline sulphate 5 X 250 micrograms
Number of subjects: 12
Study: 31865897

Group type: EXPERIMENTAL
Intervention: Repeat endovascular thrombectomy (rEVT)
Number of subjects: 3928
Study: 30429276

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAAs)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control group (matched individuals without ALS)
Number of subjects: 275
Study: 26381076

Group type: EXPERIMENTAL
Intervention: Midwife-led care
Number of subjects: 1653

Group type: COMPARATOR
Intervention: Consultant-led care
Number of subjects: 1653
Study: 24662904

Group type: EXPERIMENTAL
Intervention: Post-menopausal women
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pre-menopausal women
Number of subjects: 48
Study: 21527615

Group type: EXPERIMENTAL
Intervention: Sonography for verifying tracheal tube placement
Number of subjects: 150
Study: 17559360

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Partial elimination of H. pylori infection
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Successful eradication
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Partial elimination
Number of subjects: 80

Group type: COMPARATOR
Intervention: Failed eradication
Number of subjects: 80
Study: 17139602

Group type: EXPERIMENTAL
Intervention: Combination treatment with endothelin-receptor inhibitors, phosphodiesterase-5 inhibitors, and prostanoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (e.g., Imatinib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activators and simulators of soluble guanylyl cyclase
Number of subjects: 0
Study: 14663808

Group type: EXPERIMENTAL
Intervention: 4.8% tranexamic acid mouthwash (10 mL, 4 times a day for 7 days postoperatively)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Autologous fibrin glue (intraoperatively)
Number of subjects: 49
Study: 11198496

Group type: EXPERIMENTAL
Intervention: Asymmetric crying facies (ACF)
Number of subjects: 5532
Study: 8926685

Group type: EXPERIMENTAL
Intervention: Intense preradiation chemotherapy
Number of subjects: 133
Study: 1290924

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg/day for 4 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Capsaicin
Number of subjects: 11
Study: 6585734

Group type: EXPERIMENTAL
Intervention: 3‐mg prostaglandin E2 vaginal suppository
Number of subjects: 85

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 85
Study: 31851667

Group type: EXPERIMENTAL
Intervention: Partial standings at rounds 10, 20, and 30
Number of subjects: 22

Group type: COMPARATOR
Intervention: Randomized leagues
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Reordering of match fixtures
Number of subjects: 22
Study: 27787624

Group type: EXPERIMENTAL
Intervention: Polyurethane nasal dressing
Number of subjects: 30

Group type: COMPARATOR
Intervention: No nasal packing (control)
Number of subjects: 30
Study: 26787238

Group type: EXPERIMENTAL
Intervention: Pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone
Number of subjects: 0
Study: 24711779

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Manipulative therapy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination of manual and manipulative therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 22612596

Group type: EXPERIMENTAL
Intervention: Screening with flexible sigmoidoscopy
Number of subjects: 154900
Study: 20813580

Group type: EXPERIMENTAL
Intervention: Aerobic physical activity plus sleep hygiene education
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-physical activity plus sleep hygiene
Number of subjects: 17
Study: 17664882

Group type: COMPARATOR
Intervention: Placebo (identical in appearance to vitamin E softgel)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU softgel cap)
Number of subjects: 51
Study: 15827075

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program in a community pharmacy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 11574338

Group type: EXPERIMENTAL
Intervention: Balanced Fluid group (Hartmann's solution and 6% hetastarch in balanced electrolyte and glucose injection)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Saline group (0.9% sodium chloride solution and 6% hetastarch in 0.9% sodium chloride solution)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Balanced Fluid group
Number of subjects: 47

Group type: COMPARATOR
Intervention: Saline group
Number of subjects: 47
Study: 9576119

Group type: EXPERIMENTAL
Intervention: Enalapril 5 or 20 mg BID
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Isradipine 5 or 10 mg BID
Number of subjects: 391

Group type: COMPARATOR
Intervention: Isradipine
Number of subjects: 391

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Enalapril and Isradipine
Number of subjects: 391
Study: 8154647

Group type: EXPERIMENTAL
Intervention: Accelerated-dose tissue plasminogen activator (tPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0
Study: 3278798

Group type: EXPERIMENTAL
Intervention: Regimen A (intermittent regimen)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Regimen B (continuous regimen)
Number of subjects: 131
Study: 29788288

Group type: EXPERIMENTAL
Intervention: IgG-guided exclusion diet
Number of subjects: 97

Group type: COMPARATOR
Intervention: Healthy diet (control)
Number of subjects: 97
Study: 28078455

Group type: EXPERIMENTAL
Intervention: Laparoscopic training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Robotic training
Number of subjects: 40
Study: 24343701

Group type: EXPERIMENTAL
Intervention: DE‐CTA‐MPR
Number of subjects: 21

Group type: COMPARATOR
Intervention: CE‐MRA
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DE‐CTA‐PS‐MIP
Number of subjects: 21

Group type: COMPARATOR
Intervention: DSA
Number of subjects: 21
Study: 24252845

Group type: EXPERIMENTAL
Intervention: EPA+DHA supplementation (0, 300, 600, 900, 1800 mg daily)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 21143249

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 90
Study: 18981939

Group type: EXPERIMENTAL
Intervention: GLU + CAF (6.4% glucose plus caffeine providing 5.3 mg kg(‐1) of caffeine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: GLU (6.4% glucose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 10

Group type: COMPARATOR
Intervention: GLU
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GLU + CAF
Number of subjects: 10

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 10
Study: 16580527

Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation ablation using the NIOBE II system
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation ablation
Number of subjects: 40
Study: 14634576

Group type: EXPERIMENTAL
Intervention: Presumptive treatment with azithromycin, cefixime, and metronidazole
Number of subjects: 206

Group type: COMPARATOR
Intervention: No treatment for Trichomonas vaginalis
Number of subjects: 206
Study: 10929693

Group type: EXPERIMENTAL
Intervention: Parent transfer
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nurse transfer
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both transfer methods
Number of subjects: 15
Study: 9008498

Group type: EXPERIMENTAL
Intervention: Tolcapone 50 mg tid
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg tid
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Tolcapone 400 mg tid
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 7984589

Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS) with adjuvant intravascular laser radiation of the blood (ILRB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 60
Study: 3297181

Group type: EXPERIMENTAL
Intervention: Regular release (RR) quinidine sulfate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sustained release (SR) quinidine bisulfate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sustained release (SR) quinidine bisulfate with food (SR-F)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All three dosage regimens (RR, SR, SR-F)
Number of subjects: 6

Group type: COMPARATOR
Intervention: FPIA
Number of subjects: 6
Study: 30845243

Group type: EXPERIMENTAL
Intervention: High inhibition demands condition (75% of incongruent trials)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control condition (0% of incongruent trials)
Number of subjects: 134
Study: 28272227

Group type: EXPERIMENTAL
Intervention: 50% xenon
Number of subjects: 100

Group type: COMPARATOR
Intervention: 50% oxygen (control group)
Number of subjects: 100
Study: 24947057

Group type: EXPERIMENTAL
Intervention: Trisodium citrate (TSC)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 207
Study: 23975663

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (oxaliplatin/FU) - Arm B
Number of subjects: 126

Group type: COMPARATOR
Intervention: No induction chemotherapy - Arm A
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 126
Study: 21439823

Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m² IV on days 1, 8, 15, 22, and 29) and uracil-tegafur (300 mg/m² TID from days 1-28) with folinic acid (90 mg QD)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Paclitaxel and uracil-tegafur
Number of subjects: 31
Study: 19323672

Group type: EXPERIMENTAL
Intervention: Video-feedback intervention to promote positive parenting (VIPP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 17366000

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC, n=18)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC, n=15)
Number of subjects: 33
Study: 15311838

Group type: EXPERIMENTAL
Intervention: Fractal dimension (FD) of the skeletonized cerebral surface
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Volumes of intracranial gray matter and white matter
Number of subjects: 62
Study: 11743288

Group type: EXPERIMENTAL
Intervention: High dose conformal radiation therapy (77.4 Gy delivered to the prostate)
Number of subjects: 167
Study: 9521253

Group type: EXPERIMENTAL
Intervention: L-deprenyl (10 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8194282

Group type: EXPERIMENTAL
Intervention: Trimetrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cotrimoxazole (trimethoprim-sulfamethoxazole)
Number of subjects: 0
Study: 2913547

Group type: EXPERIMENTAL
Intervention: Cefuroxime or ceftriaxone therapy
Number of subjects: 301
Study: 1096809

Group type: EXPERIMENTAL
Intervention: cephalothin-tobramycin
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: cephalothin-ticarcillin
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: ticarcillin-tobramycin
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: ticarcillin-cephalothin
Number of subjects: 186
Study: 762245

Group type: EXPERIMENTAL
Intervention: Oxygen breathing during exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Air breathing during exercise
Number of subjects: 24
Study: 31766971

Group type: EXPERIMENTAL
Intervention: Chest compression depth of 5 cm
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Chest compression depth of 6 cm
Number of subjects: 400
Study: 27928721

Group type: EXPERIMENTAL
Intervention: 100 μg selenium supplements as tablet (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 60
Study: 26162698

Group type: EXPERIMENTAL
Intervention: Labouring deliveries
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Distal edge of the placenta
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PEG3 and PEG10
Number of subjects: 5
Study: 23951035

Group type: EXPERIMENTAL
Intervention: 80% neutral oligosaccharides (scGOS/lcFOS) and 20% pectin-derived acidic oligosaccharides (pAOS)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 113
Study: 20540083

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT)
Number of subjects: 44
Study: 18986646

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 703

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 703
Study: 17267841

Group type: EXPERIMENTAL
Intervention: Fetal fibronectin levels at 28 weeks
Number of subjects: 2353

Group type: EXPERIMENTAL
Intervention: Fetal fibronectin levels at 20-24 weeks
Number of subjects: 2353

Group type: COMPARATOR
Intervention: Antibiotic treatment at 20-24 weeks
Number of subjects: 2353
Study: 15541252

Group type: EXPERIMENTAL
Intervention: Eptifibatide (glycoprotein IIb/IIIa platelet receptor inhibitor) for 24 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 11941231

Group type: EXPERIMENTAL
Intervention: Amukine 0.06% solution
Number of subjects: 113

Group type: COMPARATOR
Intervention: Povidone iodine (Bétadine) 5% solution
Number of subjects: 113
Study: 10230996

Group type: EXPERIMENTAL
Intervention: Verbal fluency task during walking in PD-F patients
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Antiparkinsonian medications in PD-F patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 38
Study: 8706117

Group type: EXPERIMENTAL
Intervention: sumatriptan
Number of subjects: 268

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 268
Study: 2568349

Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 8
Study: 14652

Group type: EXPERIMENTAL
Intervention: Carpipramine (3 X 100 mg daily for 43 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Carpipramine (30 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Doxepine (30 days)
Number of subjects: 60
Study: 31998802

Group type: EXPERIMENTAL
Intervention: 14-CpG-based signature model
Number of subjects: 371
Study: 30977382

Group type: EXPERIMENTAL
Intervention: Lycra® gauntlets for eight hours daily for eight weeks, plus usual rehabilitation (n=27)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual rehabilitation only (n=16)
Number of subjects: 43
Study: 29270521

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 961

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 961
Study: 26283085

Group type: COMPARATOR
Intervention: Olodaterol 20 μg
Number of subjects: 494

Group type: COMPARATOR
Intervention: Olodaterol 2 μg
Number of subjects: 494

Group type: COMPARATOR
Intervention: Olodaterol 5 μg
Number of subjects: 494

Group type: COMPARATOR
Intervention: Olodaterol 10 μg
Number of subjects: 494

Group type: COMPARATOR
Intervention: Formoterol 12 μg twice-daily
Number of subjects: 494
Study: 23443830

Group type: EXPERIMENTAL
Intervention: 14-month core foods (fruit, grains, vegetables, cheese, nuts/seeds)
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: basic combination (white bread, milk, spreads, juice, ice-cream)
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: 24-month core foods (fruit, vegetables, dairy, nuts/seeds, meat, water)
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: non-core foods (white bread, spreads, sweetened beverages, snacks, chocolate, processed meat)
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Maternal age and breastfeeding cessation
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Solid food introduction timing
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Body mass index (BMI) z-score
Number of subjects: 1045
Study: 22188781

Group type: EXPERIMENTAL
Intervention: Multidimensional home-based exercise programme delivered by an exercise therapist over 12 weeks.
Number of subjects: 210

Group type: COMPARATOR
Intervention: Baseline physical activities (control group).
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Multidimensional home-based exercise programme.
Number of subjects: 210
Study: 19694864

Group type: EXPERIMENTAL
Intervention: Multifocal glasses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single-lens glasses
Number of subjects: 30